Therapy of Polycythemia Vera and Essential Thrombocythemia with Carboquone

DOI Web Site PubMed
  • NIIKURA Haruo
    Division of Hematology, Department of Internal Medicine, Fujigaoka Hospital, Showa University
  • HAGIWARA Shoji
    Division of Hematology, Department of Internal Medicine, Fujigaoka Hospital, Showa University
  • NISHIYAMA Hiroaki
    Division of Hematology, Department of Internal Medicine, Fujigaoka Hospital, Showa University
  • MORI Hiraku
    Division of Hematology, Department of Internal Medicine, Fujigaoka Hospital, Showa University
  • MOHRI Hiroshi
    Division of Hematology, Department of Internal Medicine, Fujigaoka Hospital, Showa University
  • MATSUNO Kazuhiko
    Division of Hematology, Department of Internal Medicine, Fujigaoka Hospital, Showa University
  • TERADA Hideo
    Division of Hematology, Department of Internal Medicine, Fujigaoka Hospital, Showa University

Bibliographic Information

Other Title
  • 真性多血症および本態性血小板症に対するCarboquone治療
  • シンセイ タケツショウ オヨビ ホンタイセイ ケッショウバンショウ ニ タイス

Search this article

Abstract

Twenty two patients with polycythemia vera (PV) and 11 patients with essential thrombocythemia (EF) were treated with an alkylating agent, carboquone.<br>No patients received chemotherapeutic regimen prior to carboquone therapy. Carboquone was administered orally in 0.5∼2.0mg daily dose as remission induction therapy without simultaneous administration of other chemotherapeutic agents. Most patients were administered smaller doses of carboquone (0.25∼1.0mg/day) as a maintenance therapy. Phlebotomy was combined with carboquone therapy in 16 patients with PV during remission induction.<br>All patients responded to carboquone therapy. Complete remission was obtained in 21 out of 22 patients with PV and in 10 out of 11 patients with ET. IT required median 41 days and 37 days to achieve remission in patients with PV and with ET, respectively. The median duration of remission without carboquone was 126 days and 76 days in PV and in ET, respectively.<br>No serious side effect was noted. Only one patient with ET complained of nausea and vomiting, because of which carboquone was discontinued. Two patients developed bone marrow suppression (pancytopenia) which was promptly recovered by discontinuation of carboquone.<br>These data indicate that carboquone is markedly effective for the treatment of PV and ET.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 22 (11), 1700-1707, 1981

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top